Fortress Biotech, Inc. reported its full‑year 2025 results, posting a net loss of $1.9 million, or $0.07 per share, a dramatic improvement from the $55.9 million loss ($2.69 per share) recorded in 2024. The company’s earnings fell short of the consensus estimate of a $0.42 loss per share, missing expectations by $0.39 per share.
Revenue rose 9.7% to $63.3 million, driven largely by the marketed dermatology segment, which generated $61.2 million of the total. The increase reflects stronger demand for the company’s flagship products and a favorable mix shift toward higher‑margin offerings. Gross margin contracted slightly to 67.4% from 69.4% in 2024, a result of a mix shift toward lower‑margin product lines and modest pricing pressure in the dermatology market.
Research and development expenses fell sharply, declining from $56.9 million in 2024 to $11.9 million in 2025, a 79% reduction that helped narrow the net loss. Operating expenses remained high, but the company’s cash position improved to $79.4 million from $57.3 million at the end of 2024, giving it a stronger liquidity buffer for future investments.
Management highlighted disciplined execution across its portfolio, noting the monetization of assets, regulatory approvals, and progress in high‑value clinical programs. The company also benefited from the sale of a rare‑pediatric disease priority review voucher for $205 million and the acquisition of Checkpoint Therapeutics by Sun Pharma, which provided upfront capital and a long‑term royalty stream.
Overall, Fortress Biotech’s 2025 results show a clear trajectory toward profitability, with a substantially reduced loss, revenue growth, and a healthier cash balance. However, the company still missed consensus earnings expectations, underscoring the need for continued cost discipline and revenue expansion to achieve positive earnings in the coming year.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.